Failure of adefovir 20 mg to improve suboptimal response in lamivudine-resistant hepatitis B patients treated with adefovir 10 mg and lamivudine

M. Viganò, P. Lampertico, F. Facchetti, G. Lunghi, M. Colombo

Research output: Contribution to journalArticlepeer-review

Abstract

Nine patients with lamivudine-resistant chronic hepatitis B infection who had been treated with adefovir 10 mg/day and had had a suboptimal response but did not have genotypic resistance to adefovir were treated with high-dose adefovir (20 mg/day). The response to the increased dose of adefovir was compared with the response in 15 patients with a suboptimal response who did not receive an increase in the dose of adefovir. The increase in the dose of adefovir did not lead to a significant reduction in hepatitis B DNA when compared with patients maintained on the standard dose. These data suggest that increasing the dose of adefovir in patients with a suboptimal response does not lead to an improved response.

Original languageEnglish
Pages (from-to)922-924
Number of pages3
JournalJournal of Viral Hepatitis
Volume15
Issue number12
DOIs
Publication statusPublished - Dec 2008

Keywords

  • Adefovir dipivoxil
  • Antiviral treatment
  • HBV DNA
  • Hepatitis B
  • Lamivudine resistance
  • Suboptimal response

ASJC Scopus subject areas

  • Hepatology
  • Infectious Diseases
  • Virology

Fingerprint Dive into the research topics of 'Failure of adefovir 20 mg to improve suboptimal response in lamivudine-resistant hepatitis B patients treated with adefovir 10 mg and lamivudine'. Together they form a unique fingerprint.

Cite this